ModuleDraftMedications

Study module: antithrombotics in stroke (antiplatelet vs anticoagulant) — decision concepts

Study-focused framework for antithrombotic decisions after ischemic stroke/TIA: antiplatelet vs anticoagulation based on mechanism, dual antiplatelet timing concept, and safety considerations (no dosing).

ClinicianClinicianAdvanced30 minClinical (pro)

Educational only

Educational only — antithrombotic decisions require guideline criteria and patient-specific assessment.

Get help now

Severe bleeding, head injury on antithrombotics, or suspected acute stroke is an emergency: activate local emergency response immediately. Document antithrombotic agent and last known dose time if available.

Key takeaways

  • Differentiate antiplatelet vs anticoagulant mechanisms
  • Map stroke mechanism categories to antithrombotic strategy themes
  • Describe dual antiplatelet therapy (DAPT) short-course concept in select minor stroke/TIA
  • Identify bleeding-risk counseling and monitoring themes

Mechanisms

  • Platelet inhibition
  • Coagulation pathway inhibition

Etiology → therapy themes

  • Non-cardioembolic → antiplatelet-centered strategies
  • Cardioembolic (e.g., AFib) → anticoagulation consideration

DAPT concept

  • Short course in selected patients
  • Timing matters
  • Not for all patients

Safety themes

  • Bleeding risk
  • Drug interactions
  • Peri-procedural planning

Practice check

What you’ll practice

These questions are untimed. After you answer all of them, you’ll see your score and a clear next lesson or reference step.

0 of 3 answered

Question 1

1. In secondary prevention, anticoagulation is most commonly considered when stroke mechanism is…

Question 2

2. Dual antiplatelet therapy is used only in selected situations and not for all stroke patients.

Question 3

3. A key safety theme for all antithrombotics is…

References

  1. Tier 1
    AHA/ASA 2021 Secondary Prevention Guideline
  2. Tier 1
    ESO 2021 TIA Guideline (antiplatelet/DAPT concepts)